Corpus Intelligence IC Memo — THE NEUROMEDICAL CENTER 2026-04-26 09:39 UTC
IC Memo — THE NEUROMEDICAL CENTER
Investment Committee Memorandum | LA | 27 beds | Grade C | EBITDA uplift $759K
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

THE NEUROMEDICAL CENTER

CCN 193090 | nan, LA | 27 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

THE NEUROMEDICAL CENTER is a 27-bed community hospital in nan, LA with $10.2M in net patient revenue and a 13.0% operating margin. The hospital serves a payer mix of 37.4% Medicare, 0.0% Medicaid, and 62.6% commercial.

Thesis: Turnaround. Our ML models identify $759K in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 13.0% to 20.4% (+742bps).

Net Revenue HCRIS$10.2M
Current EBITDA COMPUTED$1.3M
Operating Margin COMPUTED13.0%
Occupancy HCRIS86.7%
Revenue / Bed COMPUTED$379K
Net-to-Gross HCRIS36.5%
Distress Probability MLnan%

2. Market Context & Competitive Position

212
LA Hospitals
-3.5%
State Median Margin
134
Comparable Hospitals

LA has 212 Medicare-certified hospitals with a median operating margin of -3.5%. The target's margin of 13.0% places it above the state median. Among 134 size-comparable peers (14-54 beds), the median margin is -3.3%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (14-54), prioritizing same-state peers. 134 hospitals in the comp set.

HospitalStateBedsRevenueMargin
THE NEUROMEDICAL CENTER (Target)LA27$10.2M13.0%
UNIVERSITY HOSPITAL & CLINICSLA52$158.9M-33.4%
SPECIALISTS HOSPITAL OF SHREVELA15$79.1M21.3%
OCHSNER BAYOU LLCLA25$76.5M-0.9%
OUR LADY OF THE ANGELS HOSPITALA36$76.2M-4.9%
CENTRAL LOUISIANA SURGICAL HOSLA24$69.1M7.7%
ABBEVILLE GENERAL HOSPITALLA44$68.5M3.4%
ST. CHARLES PARISH HOSPITALLA27$64.0M-5.1%
AVALALA21$64.0M7.4%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $759K (742bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$215K+210bp18mo
Denial Rate Reduction12.0%6.5%$205K+201bp12mo
Cost to Collect4.5%2.5%$205K+200bp12mo
A/R Days Reduction5200.0%3800.0%$124K+122bp9mo
Clean Claim Rate88.0%96.0%$10K+9bp6mo

5. EBITDA Bridge

Net Collection Rate
$215K
Denial Rate Reduction
$205K
Cost to Collect
$205K
A/R Days Reduction
$124K
Clean Claim Rate
$10K
Total EBITDA Uplift$759K
Current EBITDA$1.3M
+ RCM Uplift+$759K
Pro Forma EBITDA$2.1M
Current Margin13.0%
Pro Forma Margin20.4%
WC Released (1x)$392K

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$2.0M$16.3M8.00x51.6%
Base (11x exit)10.0x11.0x$2.0M$18.6M9.13x55.6%
Bull Case9.0x11.0x$1.8M$21.8M11.86x64.0%
Bull (12x exit)9.0x12.0x$1.8M$24.3M13.24x67.6%
Bear Case11.0x10.0x$2.2M$11.9M5.29x39.5%
Bear (11x exit)11.0x11.0x$2.2M$13.8M6.14x43.8%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumStandard execution riskRCM improvement requires management buy-in and 12-18 month implementation timeline

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 134 hospitals with 14-54 beds
  • Same-state prioritization (n=135)
  • Comp margins: P25=-17.7% / P50=-3.3% / P75=5.4%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.